US1101221083 - Common Stock
The company is going through a rough patch.
The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company ("Bristol Myers" or the "Company") (NYSE: BMY)....
With a possible rotation away from the technology space, these are the undervalued healthcare stocks to consider.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bristol-Myers Squibb Company ("Bristol Myers" or the "Company") (NYSE: BMY)....
Bristol Myers Squibb Co. won accelerated approval for the first CAR-T therapy for adults with two forms of hard-to-treat leukemia or lymphoma.
Is BRISTOL-MYERS SQUIBB CO (NYSE:BMY) a Good Fit for Dividend Investing?